Stocktoria
AGENUS INC AGEN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-02-04
AGENUS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $114.2M | $103.5M | $156.3M | $98.0M | $295.7M |
| R&D expense | $79.3M | $155.5M | $234.6M | $186.7M | $178.6M |
| Operating income | -$20.2M | -$120.5M | -$159.5M | -$179.4M | $25.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Operating cash flow | -$77.2M | -$158.3M | -$224.2M | -$175.4M | $10.1M |
| Free cash flow | -$77.2M | -$158.9M | -$234.2M | -$228.4M | -$23.7M |
| Cash & equivalents | $3.0M | $40.4M | $76.1M | $178.7M | $291.9M |
| Total assets | $226.8M | $226.3M | $313.9M | $413.6M | $466.0M |
| Shareholders' equity | -$277.9M | -$326.4M | -$160.3M | -$61.3M | $47.9M |
| EPS (diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 |
Source: SEC EDGAR filings · CIK 0001098972 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.